Premium
Deoxyribozyme‐Based DNA Machines for Cancer Therapy
Author(s) -
Nedorezova Daria D.,
Fakhardo Anna F.,
Molden Tatiana A.,
Kolpashchikov Dmitry M.
Publication year - 2020
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.201900525
Subject(s) - deoxyribozyme , rna , dna , nucleic acid , cleave , computational biology , nanotechnology , genetic enhancement , cancer therapy , housekeeping gene , biology , cancer , gene , chemistry , gene expression , biochemistry , genetics , materials science
Soon after their discovery, RNA‐cleaving deoxyribozymes (RCDZ) were explored as anticancer gene therapy agents. Despite low toxicity found in clinical trials, there is no clinically significant anticancer RCDZ‐based therapy. Some of the reported disadvantages of RCDZ agents include poor accessibility to folded nucleic acids, low catalytic efficiency inside cells, and problems of intracellular delivery. On the other hand, structural DNA nanotechnology provides an opportunity to build multifunctional nano‐associations that can address some of these problems. Herein we discuss the possibility of building RCDZ‐based multifunctional DNA nanomachines equipped with RNA unwinding, cancer marker recognition, and RCDZ‐based RNA‐cleavage functions. An important advantage of such “nanomachines” is the possibility to cleave a housekeeping gene mRNA in a cancer‐cell‐specific manner. The proposed design could become a starting point for building sophisticated DNA‐based nanodevices for cancer treatment.